Sugi Predict

Sugi Predict / Compounds / SCHEMBL1965735

SCHEMBL1965735

SCHEMBL1965735

CC(C)(C)OC(=O)N1CCC(F)CC1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ RECQL P46063 1/20 0.61
▸ HPGD P15428 1/20 0.60
▸ EPHX1 P07099 1/20 0.57
▸ GPR119 Q8TDV5 6/20 0.53
▸ MAPT P10636 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ THRB P10828 1/20 0.51
▸ PTPN2 P17706 1/20 0.51
▸ PTPN1 P18031 1/20 0.51
▸ PTPN6 P29350 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.49
▸ NPC1 O15118 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ DPP4 P27487 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14480194 0.90 RECQL (0.52) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL1733236 0.89 HPGD (0.53) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL3792583 0.89 HPGD (0.53) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL1733238 0.89 HPGD (0.53) USP2SMN1; SMN2RECQLHPGDEPHX1
Hydrochloric Acid SCHEMBL30496259 0.87 HPGD (0.51) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL8018 0.86 HPGD (0.58) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL310117 0.86 GPR119 (0.67) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL696090 0.86 HPGD (0.62) USP2SMN1; SMN2RECQLHPGDEPHX1
Hydrochloric Acid SCHEMBL307023 0.85 HPGD (0.57) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL16897017 0.84 HPGD (0.60) USP2SMN1; SMN2RECQLHPGDEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 — — US disclosed
CN-115427406-B 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same 株式会社钟根堂 2025-03-04 — — CN disclosed
CN-113302184-B 1,3, 4-Oxadiazolinone compounds and medicaments 日本新药株式会社 2024-11-22 — — CN disclosed
EP-4419532-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-08-28 — — EP disclosed
CN-118480029-A 2-Aminopyrimidine compound or salt thereof, and preparation method and application thereof 励缔(杭州)医药科技有限公司 2024-08-13 — — CN disclosed
CN-112867712-B Carboxamide as ubiquitin-specific protease inhibitor 瓦洛早期发现股份有限公司 2024-07-16 — — CN disclosed
CN-112469707-B Preventive or therapeutic agent for spinal muscular atrophy 利伯纳生物科学株式会社 2024-06-21 — — CN disclosed
CN-112661751-B Heterocyclic compounds as BCL-2 inhibitors 南京天印健华医药科技有限公司 2024-06-14 — — CN disclosed
CN-118063455-A Method for preparing Ruimei pam intermediate 尚科生物医药（上海）有限公司 2024-05-24 — — CN disclosed
CN-117940427-A Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof 卡里克治疗有限公司 2024-04-26 — — CN disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 — — US disclosed
US-20070254881-A1 Pyrazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 — — US disclosed
EP-1785418-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-16 — — EP disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 — — EP disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 — — US disclosed
CN-1812980-A Piperidinyl-and piperazinyl-alkylcarbamate derivatives, their preparation and their therapeutic use SANOFI AVENTIS (FR) 2006-08-02 — — CN disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 — — US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 — — EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 — — EP disclosed
WO-2004076434-A1 DIPEPTIDYL PEPTIDASE INHIBITORS AIC (BE) 2004-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254881-A1 Pyrazole Derivative PTGER1, PTGS1, PTGER2 USP2 3692/4885SMN1; SMN2 3490/4885RECQL 2759/4885
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 USP2 3881/4885SMN1; SMN2 3778/4885RECQL 2722/4885
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 USP2 2022/4885SMN1; SMN2 18/4885RECQL 50/4885
US-20080064682-A1 Pyrazole Derivatives NAT1, AR, CBR3 USP2 3366/4885SMN1; SMN2 3660/4885RECQL 4074/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 USP2 3810/4885SMN1; SMN2 3027/4885RECQL 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.